Literature DB >> 10431840

Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma.

J E König1, E Tolnay, T Wiethege, K M Müller.   

Abstract

Angiogenesis is an important part of normal and pathological processes, including tumour growth, metastasis, inflammation and wound healing. VEGF is the best known angiogenic factor, implicated in tumour-associated microvascular hyperpermeability and carcinogenesis. We investigated 103 malignant pleural mesotheliomas, analysing the expression of vascular endothelial growth factor using immunohistochemistry and in situ hybridization. The grade of microvessel density was assessed with the aid of anti-factor-VIII antibodies. An increased expression of VEGF was found in biphasic and epithelioid mesotheliomas, correlating in a statistically significant manner (P<0.042). In situ hybridization confirmed the specificity of VEGF mRNA expression. There was a robust correlation between VEGF expression and increased microvessel density (P<0.001), and positive mesotheliomas had significantly higher microvessel densities than negative specimens. There was also a significant correlation between microvessel density and histological pattern. As growth pattern tended towards biphasic and sarcomatoid mesotheliomas the density of micovessels decreased (P<0.05).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10431840     DOI: 10.1007/s004280050388

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  13 in total

1.  Mesothelioma: a review.

Authors:  Frank E Mott
Journal:  Ochsner J       Date:  2012

2.  Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905).

Authors:  Anne S Tsao; James Moon; Ignacio I Wistuba; Nicholas J Vogelzang; Gregory P Kalemkerian; Mary W Redman; David R Gandara; Karen Kelly
Journal:  J Thorac Oncol       Date:  2017-06-06       Impact factor: 15.609

Review 3.  Novel therapies in phase II and III trials for malignant pleural mesothelioma.

Authors:  Marjorie G Zauderer; Lee M Krug
Journal:  J Natl Compr Canc Netw       Date:  2012-01       Impact factor: 11.908

4.  Vascular endothelial growth factor levels in childhood acute lymphoblastic and myeloblastic leukemia.

Authors:  Göksel Leblebisatan; Bülent Antmen; Ilgen Saşmaz; Yurdanur Kilinç
Journal:  Indian J Hematol Blood Transfus       Date:  2011-08-17       Impact factor: 0.900

5.  Impact of tumor angiogenesis in peritoneal mesothelioma after radical cytoreduction and hyperthermic intraperitoneal chemotherapy.

Authors:  Terence C Chua; Peng Yao; Javed Akther; David L Morris
Journal:  Pathol Oncol Res       Date:  2009-10-01       Impact factor: 3.201

Review 6.  Peritoneal mesothelioma.

Authors:  R N Taub; M L Keohan; J C Chabot; K S Fountain; M Plitsas
Journal:  Curr Treat Options Oncol       Date:  2000-10

7.  Stabilization of a progressive hemangioblastoma under treatment with thalidomide.

Authors:  Maria Piribauer; Thomas Czech; Karin Dieckmann; Peter Birner; Johannes A Hainfellner; Daniela Prayer; Barbara Fazeny-Dörner; Georg Weinländer; Christine Marosi
Journal:  J Neurooncol       Date:  2004-02       Impact factor: 4.130

Review 8.  Malignant pleural mesothelioma.

Authors:  Anne S Tsao; Ignacio Wistuba; Jack A Roth; Hedy Lee Kindler
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

Review 9.  Novel and Promising Systemic Treatment Approaches in Mesothelioma.

Authors:  Elizabeth Dudnik; Daniel Reinhorn; Liran Holtzman
Journal:  Curr Treat Options Oncol       Date:  2021-08-23

Review 10.  Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma.

Authors:  Francesca Napoli; Angela Listì; Vanessa Zambelli; Gianluca Witel; Paolo Bironzo; Mauro Papotti; Marco Volante; Giorgio Scagliotti; Luisella Righi
Journal:  Cancers (Basel)       Date:  2021-05-24       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.